EpiVax führt KI-gestützte Modelle zur Vorhersage der Immunogenität ein

ISPRI™Positive

AI Analysis

Summary

EpiVax announced the introduction of AI-powered enhancements to its ISPRI™ platform, a proprietary in-silico platform for assessing immunogenicity risk of biotherapeutics. The new version incorporates machine learning capabilities to improve predictive accuracy.

Importance:3/10

Sentiment:

0.60

platform technologyAI/machine learningimmunogenicityin silicoproduct announcement

Read the original article

Published by PR Newswire Biotech on September 3, 2026 5:22 AM

Read Original